Vigmed launches unique arterial catheter to the market 2015

In September 2013, Vigmed signed a Contract Manufacturing Agreement with AMB
Industri AB in Emmaboda, Sweden. At that time, Vigmed chose to keep the details
of the agreement secret. The first assembly lines are now being delivered to AMB
and pre-sales activities in prioritized markets are ready to commence.
Therefore, Vigmed considers it necessary to release information about the
upcoming launch of a unique safety Arterial Catheter.
Vigmed’s strategic business area is defined as safety products giving access to
the cardiovascular system. Until now, Vigmed’s focus has been on the intravenous
catheter market, which is a large and, compared to the arterial catheter market,
relatively competitive market. During the autumn of 2015 Vigmed plans to launch
a safety arterial catheter as a natural move to provide products giving access
to both the venous and the arterial side of the cardiovascular system.

“The Arterial catheter market is smaller than the one for I.V. catheters, but as
it is a premium priced market with less competition, we expect our new product
to contribute with earnings rather fast” says Finn Ketler, CEO, Vigmed. He
continues, “It should also be noted, that when launching the new product, our
European distribution network will be in place and given the market demand, our
partners are welcoming this new opportunity”.

The manufacturer AMB's CEO Tomas Magnusson is delighted: "Vigmed’s arterial
catheter is a perfect project for us as a provider of complex medical devices”,
he says. “Through close cooperation between Vigmed, AMB, our subsidiary
Tingverken and our automation supplier we have full control of the entire
process. The project timeline is 18 months from start of the project to
production, and we are right on schedule.”
For further information contact:

Chairman of the Board, Lennart Holm, + 46 70 630 85 62 or CEO, Finn Ketler + 46
42 600 5311
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries by offering the market unique needle-protected products.
Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20
employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm
(ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the
Company’s Certified Advisor.

Additional information such as company description, a video presentation and
risk factors can be found on Vigmed’s website: www.vigmed.com/investor